FibroBiologics CSO buys $0.5 million in stock in private placement

FibroBiologics, Inc. (Nasdaq: FBLG) said it closed a private placement on September 15, 2026 with Chief Scientific Officer Hamid Khoja, Ph.D. The company sold Khoja 298,508 shares of common stock along with warrants to buy up to another 298,508 shares, priced at market under Nasdaq rules.¹

The combined price for each share and warrant was $1.675, matching the stock's Nasdaq closing bid of $1.55 on September 14, 2026, plus $0.125 for the warrant.¹ The warrants carry a $1.55 exercise price, are exercisable immediately, and run for five years.¹

Gross proceeds came to about $0.5 million before expenses, and the company said it plans to use the money for general corporate purposes and working capital.¹ A corresponding Form D filing confirmed the deal terms: the total offering amount and amount sold were both listed as $500,001, covering the 298,508 shares plus warrants exercisable at $1.55 per share for another 298,508 shares.² The filing listed one investor in the offering.²

The transaction was exempt from registration. FibroBiologics said the securities were offered under the exemption in Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, and have not been registered under the Securities Act or state securities laws.¹

Separately, the same 8-K disclosed that FibroBiologics held a Special Meeting of Stockholders on September 17, 2026. Shares representing 3,431,761 votes were represented at the meeting out of 8,283,193 votes entitled to be cast as of the July 20, 2026 record date.¹ Shareholders approved a Nasdaq-rule proposal tied to warrants issued under a June 25, 2026 securities purchase agreement and a November 10, 2025 engagement letter with H.C. Wainwright & Co., with the vote recorded as 3,153,098 for, 258,217 against, and 20,446 abstaining.¹